Structure-Based Optimization and Biological Evaluation of SARS-CoV-2 3CLpro Covalent Inhibitors

18 September 2024, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

The global emergence of COVID-19, caused by SARS-CoV-2, has underscored the critical need for effective antivirals against coronaviruses. The 3-chymotrypsin-like protease (3CLpro) of coronavirus has been a primary target for drug development due to its critical role across various coronaviruses. Following our initial report, this study focuses on the structure-based optimization of 3CLpro covalent inhibitors. With the guidance of molecular docking and covalent binding parameters measured from an innovative isothermal titration calorimetry-kinetic competition (ITC-KC) assay, we optimized and synthesized series of potent covalent inhibitors with antiviral activity in cell-based assays.

Keywords

3CLpro
inhibitors
COVID19
structure-based drug design

Supplementary materials

Title
Description
Actions
Title
Supporting information
Description
Dose-Response Curves, Isothermal Titration Calorimetry data, Compound Purity, Synthetic Routes and NMR Spectra.
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.